Cosciens Biopharma Stock Piotroski F Score
| CSCI Stock | 3.13 0.04 1.29% |
COSCIENS | Piotroski F Score |
At this time, it appears that COSCIENS Biopharma's Piotroski F Score is Very Weak. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
0.0
Piotroski F Score - Very Weak
| Current Return On Assets | N/A |
| Change in Return on Assets | N/A |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Decreasing |
| Asset Turnover Growth | N/A |
| Current Ratio Change | N/A |
| Long Term Debt Over Assets Change | Lower Leverage |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | N/A |
COSCIENS Biopharma Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to COSCIENS Biopharma is to make sure COSCIENS is not a subject of accounting manipulations and runs a healthy internal audit department. So, if COSCIENS Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if COSCIENS Biopharma's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 1.7 M | 1.7 M |
|
| |||||
| Non Current Liabilities Total | 2.2 M | 1.9 M |
|
| |||||
| Total Assets | 35.6 M | 31.4 M |
|
| |||||
| Total Current Assets | 15.6 M | 14.8 M |
|
|
COSCIENS Biopharma F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between COSCIENS Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards COSCIENS Biopharma in a much-optimized way.
Click cells to compare fundamentals
About COSCIENS Biopharma Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Total Assets |
|
About COSCIENS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze COSCIENS Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of COSCIENS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of COSCIENS Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:Check out COSCIENS Biopharma Altman Z Score, COSCIENS Biopharma Correlation, COSCIENS Biopharma Valuation, as well as analyze COSCIENS Biopharma Alpha and Beta and COSCIENS Biopharma Hype Analysis. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.